$OGEN News

Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum

Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update

Oragenics Advances Phase IIa Trial With 9 Participants Dosed; Recieved NYSE American Non Compliance Letter, Has 45 Days From Receipt Of The Deficiency Letter Within Which To Submit A Plan To Regain Compliance With The Continued Listing Standards

Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling

Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21

ORAGENICS PROVIDES INVESTOR UPDATE

Oragenics Q1 EPS $(0.51) Up From $(3.60) YoY

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Oragenics Says 2 Patients And 8 Study Drug Doses Administered In Ongoing Phase Iia Clinical Trial Evaluating ONP-002, Lead Candidate For Treatment Of Mild Traumatic Brain Injury

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Oragenics Doses First Patient In Phase IIa Clinical Trial of ONP-002

Reported Earlier, Oragenics Receives Going Concern Audit Opinion In Annual Report For Fiscal Year Ended December 31, 2025

Reported Earlier, Oragenics Receives Going Concern Audit Opinion In Annual Report For Fiscal Year Ended December 31, 2025

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

ORAGENICS FILES ANNUAL REPORT ON FORM 10-K

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

Oragenics Completes First Site Initiation Visit For Its Phase IIa Clinical Study Of ONP-002 In Australia

ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION